Immatics N.V. Share Price & Technical Analysis
IMTX · $11.62 (+5.06%)
Healthcare / Biotechnology
$11.62
+5.06%
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics…
Price chart
Seasonality
May has 4 positive and 1 negative years (last 5 years shown)
6% return in May, 19% avg return in past 3 year May month.
13% return in 2026, 27% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -9% | 8% | -3% | 10% | 6% | – | – | – | – | – | – | – | 13% |
| 25 | -24% | -19% | 2% | 14% | 10% | -2% | 19% | -19% | 67% | 19% | 7% | 0% | 74% |
| 24 | 9% | 10% | -16% | -6% | 10% | 5% | 3% | -7% | 3% | -19% | -9% | -14% | -33% |
| 23 | -7% | 5% | -19% | 4% | 38% | 16% | 3% | -1% | -3% | -34% | 16% | 19% | 39% |
| 22 | -24% | -22% | 0% | -1% | -6% | 13% | 28% | 14% | -22% | 12% | -8% | -19% | -36% |
Monthly return % by calendar month · historical pattern, not a forecast
Neutral · Strong · Uptrend
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes Anzu-cel (IMA203), a one-time infusion PRAME cell therapy, which is in Phase 2 trial; IMA203CD8, a cell therapy product that is in Phase 1 clinical trial; IMA204 that targets tumor stroma, which is in Phase 1 clinical trial; and Anzu-cel in combination with Moderna's PRAME cell therapy enhancer (mRNA-4203), which is in Phase 1 clinical trial. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$1.51B
P/E ratio
—
52W high
$12.41
52W low
$4.93
Volume
4,18,158
Beta
1.31
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Immatics N.V. share price today?
- Immatics N.V. (IMTX) last traded around $11.62 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does IMTX have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for IMTX. Download the app for real-time alerts.
- How can I analyze Immatics N.V. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.